A Phase 3, Multicenter, Open-label, Long-term Extension Study of Apremilast in Children 2 Years of Age or Older With Oral Ulcers Associated With Behçet's Disease or 5 Years of Age or Older With Juvenile Psoriatic Arthritis
Latest Information Update: 30 Jun 2025
At a glance
- Drugs Apremilast (Primary)
- Indications Behcet's syndrome; Juvenile rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 24 Jun 2025 Planned End Date changed from 30 Dec 2032 to 17 Mar 2036.
- 24 Jun 2025 Planned primary completion date changed from 30 Dec 2032 to 17 Mar 2036.
- 14 Feb 2025 Planned End Date changed from 28 Mar 2036 to 30 Dec 2032.